Rhodes Linda
Known title: DirectorCIK: 0001336284
Associated companies
Transaction History
| ZTS | ▼ Sell | Other | 541 | $93K | 5/21/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 2,441 | — | 5/21/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,463 | — | 2/10/2024 | View on chart |
| ZTS | ▼ Sell | Other | 322 | $64K | 2/10/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,493 | — | 2/8/2024 | View on chart |
| ZTS | ▼ Sell | Other | 329 | $64K | 2/8/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,626 | — | 2/11/2023 | View on chart |
| ZTS | ▼ Sell | Other | 358 | $57K | 2/11/2023 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 2,673 | — | 2/12/2022 | View on chart |
| ZTS | ▼ Sell | Other | 589 | $117K | 2/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating
Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.